ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Dako, Drugmakers, Join On Diagnostics

by Marc S. Reisch
October 5, 2015 | APPEARED IN VOLUME 93, ISSUE 39

Merck KGaA and Pfizer will collaborate with diagnostics expert Dako to develop a companion diagnostic test for avelumab. The two drug firms are jointly developing avelumab for the treatment of Merkel cell carcinoma, a rare and aggressive type of skin cancer. The antibody is now undergoing a Phase II study. FDA recently granted it orphan drug status.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment